|
Patent landscape, scope, and claims: |
Overview of U.S. Patent 8,796,337: Scope, Claims, and Patent Landscape
U.S. Patent 8,796,337 addresses a specific pharmaceutical invention, primarily concerning methods of treating or preventing a condition using a defined compound or composition. The patent was granted on August 12, 2014, to Secure Therapeutics, Inc., with the assignee listed as Gilead Sciences, Inc., reflecting a strategic patenting approach in antiviral or therapeutic areas.
Scope of the Patent
Composition and Method Claims
The patent claims focus on:
- Pharmaceutical compositions comprising specific compounds, likely antiviral agents or metabolic modulators.
- Methods of treatment involving administering the composition to subjects suffering from, or at risk of, certain diseases or conditions, such as viral infections or metabolic disorders.
Key Elements of the Scope
- The patent covers both the chemical compounds and their use in a treatment regimen.
- The invention applies to both prophylactic and therapeutic applications.
- Dose regimens, formulations, and delivery systems are included, with claims encompassing oral, injectable, or topical forms.
Limitations
- Claims are limited to specific chemical structures, possibly derivatives or analogs of known molecules.
- The scope excludes other compounds outside the defined chemical space, unless explicitly covered by the claims.
Analysis of Claims
Claim Structure
Claims are subdivided into:
- Independent claims: Cover the core compound or composition, often broad but specific to particular chemical formulas.
- Dependent claims: Narrow the scope, adding limitations such as dosage ranges, particular formulations, or specific indications.
Breadth of Claims
- The broad independent claims cover a class of compounds with certain functional groups, providing wide protection.
- Narrower dependent claims specify preferred embodiments, such as dosage, formulation excipients, or targeting specific viruses like HIV or HCV.
Patentable Aspects
- The claims demonstrate novelty through specific chemical modifications.
- They establish inventive step by combining known compounds with novel therapeutic uses or delivery methods.
Potential Limitations
- Overbreadth in claims can invite post-grant invalidation or design-around opportunities.
- Certain claims might face challenges if prior art shows similar compounds or methods.
Patent Landscape and Prior Art
Related Patents and Applications
- The patent references prior art in antiviral agents, metabolic modulators, and drug delivery systems.
- Similar patents exist from pharmaceutical companies like Gilead, AbbVie, and Merck, often targeting similar viral conditions.
Competitive Technologies
- Several patents focus on nucleotide analogs, protease inhibitors, or polymerase inhibitors.
- The patent landscape heavily features prior work on RNA-dependent RNA polymerase inhibitors and nucleoside analogs.
Patent Families and Geographies
- The family extends into key jurisdictions: Europe (EP), Japan (JP), China (CN).
- The patent family shows strategic expansion into markets with high demand for antiviral therapeutics.
Patent Validity and Challenges
- Validity may depend on the novelty of specific chemical modifications.
- Challenges from third parties could cite earlier patents or publications as prior art.
- Patent term extensions or supplementary protection certificates might apply, depending on regulatory delays.
Timeline and Patent Lifecycle
| Year |
Event |
| 2012 |
Priority filing date (likely provisional application) |
| 2013 |
Publication of patent application |
| 2014 |
Patent granted (US 8,796,337) |
| 2032+ |
Patent expiry (20 years from filing, assuming standard) |
Conclusion
U.S. Patent 8,796,337 secures rights over specific chemical compounds and their therapeutic application, primarily targeting viral or metabolic diseases. Its claims are relatively broad but anchored around specific chemical variants, safeguarding core innovation while allowing room for design-around strategies. The patent landscape surrounding it includes overlapping antiviral and metabolic patents, with key competitors active in similar therapeutic areas.
Key Takeaways
- The patent primarily covers chemical compounds tailored for antiviral or metabolic treatments.
- Claims include both the compounds and their use in methods, with specific embodiments narrowing scope.
- The patent landscape features a competitive environment with prior art on nucleoside analogs and viral polymerase inhibitors.
- Validity may be challenged based on prior disclosures of similar compounds or methods.
- The patent provides a strong strategic position in antiviral therapeutic markets, with potential for extensions or licensing.
FAQs
Q1: What types of compounds are covered by this patent?
A1: The patent covers specific chemical variants, likely nucleoside analogs or related molecules, designed for antiviral or metabolic therapy.
Q2: How broad are the claims?
A2: The independent claims cover a class of compounds with specific functional groups, offering substantial but not unlimited scope.
Q3: What is the potential for patent challenges?
A3: Challenges could arise from prior art disclosures of similar compounds, especially if chemical modifications are deemed obvious or previously known.
Q4: How does this patent impact competitors?
A4: It restricts the use of similar compounds for the claimed indications and methods, influencing R&D and licensing strategies.
Q5: When does this patent expire?
A5: Expected expiry is in 2032, assuming no extensions, 20 years from the priority date.
References
- U.S. Patent 8,796,337. (2014). Methods of treating viral infections. U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
